"Deviation" cells suggest that immunotherapy is invalid
October 17, 2018 Source: Health News Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Professor Zhu Bo, director of the Institute of Cancer Research, Xinqiao Hospital, Army Military Medical University, through a series of clinical studies, found a class of "shifted" erythroid precursor cells (EPC cells) in the blood of cancer patients. This research results explain the reasons why antibody immunotherapy is ineffective in the treatment of some cancer patients, and provides new ideas for improving the efficacy of immunotherapy. The research paper was published online in the latest issue of the international medical journal Nature Medicine.
Zhu Bo introduced that in recent years, the tumor immunotherapy represented by PD-1/PD-L1 antibody has made a major breakthrough and has become one of the important means of clinical cancer treatment, but the effective rate in clinical practice is only 20% to 30%. . The reason is that, on the one hand, tumor cells can evolve continuously to escape immune recognition; on the other hand, tumor patients can produce a variety of cells with immunosuppressive effects.
Zhu Bo's research team cooperated with Professor Ye Lilin of the Institute of Immunology of the Army Military Medical University, Professor Li Qijing of Duke University, and Professor Yu Jia of the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences. After nearly 8 years of hard work, the spleen and liver of tumor-bearing mice. A new EPC-derived immunosuppressive cell (CD45+CD71+TER119+, CD45+EPCs) was found in peripheral blood of peripheral blood and tumor patients. Under normal circumstances, EPC cells should be differentiated into normal red blood cells, but such cells cannot differentiate properly on the one hand, causing anemia in tumor patients, and inhibiting CD8+ T cell-mediated immune responses by secreting reactive oxygen species (ROS). The anti-virus/bacteria and anti-tumor immune response function of tumor patients declines, and it belongs to the “bear child†in the cell. It is precisely because of the "trick or treat" of such "bear children" that the efficacy of antibody immunotherapy is limited.
Zhu Bo's research group is currently conducting more in-depth research, hoping to better "renovate" this group of cells in cancer patients, relieve their effects on anti-tumor immunity, improve the efficacy of tumor immunotherapy, and allow more cancer patients to be cured.
Phenibut HCL, sold under the brand names Anvifen, Fenibut, and Noofen among others,is acentral nervous system depressant with anxiolytic and stimulant effects which is used in the treatment of anxiety, insomnia, and for a variety of other indications.It is usually takenby mouth as a tablet, but can also be given as an intravenous infusion.
Phenibut HCL is used for anxiety, fear, trouble sleeping (insomnia), tension, stress, fatigue, post-traumatic stress disorder (PTSD), depression, alcoholism, and irregular heartbeat. It is also used for improving memory, learning, and
phenibut hcl australia,phenibut hcl and acid,phenibut hcl adalah
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropics.com